SCHEMBL29540673

SCHEMBL29540673

COC(=O)[C@@H](Cc1ccccc1)NS(=O)(=O)c1ccc(OC)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.73
MMP9 P14780 6/20 0.73
BMP1 P13497 2/20 0.66
POLB P06746 2/20 0.62
ADAMTS4 O75173 1/20 0.60
MMP1 P03956 2/20 0.59
MMP13 P45452 2/20 0.59
KEAP1 Q14145 1/20 0.59
MMP3 P08254 1/20 0.59
ALDH1A1 P00352 3/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
MAPT P10636 1/20 0.57
CA12 O43570 1/20 0.57
CA2 P00918 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
CTSL P07711 1/20 0.57
CTSS P25774 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323453 1.00 MMP2 (0.73) MMP2MMP9BMP1POLBADAMTS4
SCHEMBL6323452 1.00 MMP2 (0.73) MMP2MMP9BMP1POLBADAMTS4
SCHEMBL22234044 0.91 MMP2 (0.86) MMP2MMP9POLBADAMTS4MMP1
SCHEMBL6081543 0.91 MMP2 (0.86) MMP2MMP9POLBADAMTS4MMP1
SCHEMBL3718143 0.91 MMP2 (0.86) MMP2MMP9POLBADAMTS4MMP1
SCHEMBL27568136 0.91 POLB (0.70) MMP2MMP9POLBADAMTS4MMP1
SCHEMBL15943338 0.90 MMP2 (0.75) MMP2MMP9POLBADAMTS4MMP1
SCHEMBL20335146 0.88 CTSL (0.67) MMP2MMP9POLBADAMTS4ALDH1A1
SCHEMBL14534184 0.88 CTSL (0.67) MMP2MMP9POLBADAMTS4ALDH1A1
SCHEMBL20335144 0.88 CTSL (0.67) MMP2MMP9POLBADAMTS4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12122742-B2 Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2024-10-22 US disclosed
US-20220112160-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2022-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112160-A1 SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 MMP2 2203/4885MMP9 2550/4885BMP1 4125/4885
US-12122742-B2 Small molecule direct inhibitors of KEAP1-NRF2 protein-protein interaction KEAP1, NFE2L2, HMOX1 MMP2 2203/4885MMP9 2550/4885BMP1 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.